Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Investigation of MEDI4736 (Durvalumab) and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors

NCT03911557 is registered in ClinicalTrials.gov with John L. Villano, MD, PhD as lead sponsor.

NCT NCT03911557
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03911557 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Investigation of MEDI4736 (Durvalumab) and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors
Lead sponsor
John L. Villano, MD, PhD
Phase
Phase 2
Overall status
Completed
Start date
June 8, 2019
Completion date
October 10, 2025
Enrollment
14 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

tumor, solid